5 billion yuan Wuxi Guolian AstraZeneca Zhongjin Medical Fund landing

　　On August 4th, 2022, the Taihu Bay Life and Health Future Conference was held in Wuxi. The theme of this conference is "beyond mutual integration, health and wisdom", aiming to gather high-end resources in the innovation ecosystem in the field of life and health industry at home and abroad, build a domestic first-class and internationally renowned investment and financing service platform for China's life and health industry, a platform for technical exchange and cooperation, a platform for releasing industry trends, and a platform for gathering high-end talents in the industry in the Taihu Lake Bay, fully demonstrate new technologies, new formats, and new models in the field of life and health, optimize the innovation ecosystem of the biomedical industry, promote industrial innovation and upgrading, and promote the development of China's biomedical industry.

　　At the opening ceremony, Guolian Group, AstraZeneca, and CICC Capital officially announced their intention to cooperate in a major strategic partnership, with the three parties planning to raise a total of RMB 5 billion for the Wuxi Guolian AstraZeneca CICC Medical Fund. The three parties have been working together in the biopharmaceutical and health industry for many years. In previous collaborations, they have jointly invested in more than ten projects and explored multiple potential enterprises such as Anshun Yuan and Xibeiman Biotechnology in multiple areas of Wuxi. The invested companies, such as Ke Rui Chi, Yue Er Gene, and Tian Ke Ya, have been listed on the "2022 Future Medical Top 100 Series List" of Arterial Network, and Heyu Medical has successfully landed on the Hong Kong Stock Exchange on October 13, 2021. This medical industry fund will focus more on sub sectors such as digital healthcare, innovative drugs, and precision medical testing, and fully leverage the local location advantages and comprehensive financial service capabilities of Guolian Group. At the same time, it will work together with AstraZeneca's industrial advantages and CICC Capital's financial resources to promote the integration of medical and health resources in Wuxi and across the country, injecting new momentum into the iteration of the health industry and economic development in the Wuxi region.